TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Being Patient report describes posterior cortical atrophy (PCA), a dementia syndrome that can first affect how people process visual and spatial information rather than memory. The report highlights delayed diagnosis, the need to rule out eye conditions, and limited evidence for treatments specifically in PCA.
A Being Patient report describes how posterior cortical atrophy (PCA) can begin with problems processing visual information and judging space, even when the eyes themselves are not the cause. The account follows Andrew Reid, who received a PCA diagnosis at age 56 after visual and everyday difficulties were initially attributed to other problems, illustrating why the syndrome can be hard to recognize.
PCA is a syndrome in which damage to brain regions involved in visual and spatial processing affects tasks such as reading, recognizing objects, navigating and judging distance. The report says symptoms can also include sensitivity to bright light and difficulty locating or using objects. As the condition progresses, dressing, eating and other routine activities may become harder. Later, some people also develop changes in memory, speech, language or executive function.
Reid told Being Patient that he first struggled to see his keyboard and write simple emails. A close call while driving prompted an emergency department visit, where he was diagnosed with epilepsy, according to the report. After about a year of treatment without his symptoms resolving, he and his family reached a brain clinic and received the PCA diagnosis. Reid’s wife, Karina, described the effect on eating: “It’s like his brain holds the image for a bit, and then it’s gone.”
The report says PCA is most often associated with Alzheimer’s disease, which underlies the syndrome in about 80 percent of cases cited in the article. Other reported causes include dementia with Lewy bodies, prion disease and other neurodegenerative conditions. The report describes evaluation as involving eye examinations to rule out eye disease, tests for other possible causes, cognitive assessment and brain imaging; tests for Alzheimer’s-related biological markers may also help identify the underlying cause.
Why Visual Symptoms Delay Diagnosis
PCA matters because a person may seek help for what appears to be an eyesight problem while the difficulty is actually in how the brain interprets visual input. That mismatch can lead to repeated eye appointments or an initial diagnosis that does not explain the symptoms. Being Patient reports that Reid visited an optometrist three times without an eye problem being identified, before his eventual diagnosis.
Delayed recognition can affect safety and daily life: problems with navigation, distance judgment and seeing objects can make driving, dressing and eating difficult. It also shapes the support people need. As University College London researcher Keir Yong told Being Patient, services designed around memory problems may not fit people whose main challenges are movement, self-care and visual processing, while memory and insight may remain comparatively intact.
The report says medicines used for Alzheimer’s or other underlying diseases may be considered, but evidence of benefit specifically for PCA is limited. That distinction matters for patients and families weighing care options: the underlying cause, symptoms and eligibility for a medicine are not the same for every person.
Products Worth Considering
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
As an affiliate, we earn on qualifying purchases.
How PCA Differs From Typical Alzheimer’s
PCA is described in the report as an atypical form of early-onset Alzheimer’s when Alzheimer’s is its cause, rather than a condition defined by memory loss at the outset. Its early effects center on the back of the brain, where visual and spatial information is processed. The report gives an average age of symptom onset of 59, while noting that the symptoms can be mistaken for eye disease or other neurological problems.
Diagnosis therefore requires more than checking visual acuity. The report says clinicians may use a detailed eye examination to exclude conditions affecting the eyes, blood work to check for metabolic causes, cognitive testing and brain imaging focused on the relevant brain regions. Blood or cerebrospinal fluid tests and amyloid PET imaging may help establish whether Alzheimer’s is behind the syndrome.
There is no cure for PCA, according to the report. Doctors may prescribe symptom-targeting drugs used for Alzheimer’s, such as cholinesterase inhibitors, or medicines associated with dementia with Lewy bodies when that is the underlying cause. The source cautions that evidence for these treatments in PCA itself is limited. It also cites a 2026 study reporting that many people with atypical Alzheimer’s, including PCA, may not qualify for certain drugs; the report says visual demands in cognitive tests can contribute to that outcome.
What PCA Research Cannot Yet Answer
The source does not establish how well Alzheimer’s medicines work for people with PCA specifically. It says treatment evidence is limited and that eligibility for some newer Alzheimer’s drugs may be a problem for people with atypical symptoms. The degree to which testing adjustments might change access is not specified.
It is also not clear from the report how long diagnosis takes on average, how often PCA is initially mistaken for a particular condition, or how the reported 80 percent estimate was calculated. Those figures should not be inferred from Reid’s individual experience. Yong told Being Patient that a screening test for optometrists is being developed with the UK Biobank and is being validated across eye and neurology clinics; the report does not provide results or a timeline for its availability.
Validation and Individualized Support
The next reported research step is validation of the proposed optometrist screening test across eye and neurology clinics. The source gives no date for completion or for possible clinical use, so its performance and effect on diagnostic delays remain unknown.
For people being assessed, the report describes a pathway that first rules out eye and other medical causes, then examines cognitive function and brain imaging, with additional Alzheimer’s biomarker tests where appropriate. Treatment and practical support depend on the person’s symptoms and the cause of PCA. The report also points to physical and occupational therapy as areas of support, while emphasizing that services may need to address navigation and daily activities, not only memory.
Key Questions
What is posterior cortical atrophy?
Posterior cortical atrophy is a syndrome that affects brain systems used to process visual and spatial information. It can make reading, navigation, object recognition and everyday tasks difficult, even when the eyes are not the source of the problem.
Does PCA always mean Alzheimer’s disease?
No. The Being Patient report says Alzheimer’s is the underlying cause in about 80 percent of cases cited, while other reported causes include dementia with Lewy bodies, prion disease and other neurodegenerative conditions.
How is PCA diagnosed?
Evaluation may include an eye examination to rule out eye disease, tests for other medical causes, cognitive testing and brain imaging. Blood, cerebrospinal fluid or amyloid PET tests may help determine whether Alzheimer’s is the underlying cause. A clinician determines which tests are appropriate.
Is there a cure or a treatment that works for PCA?
The report says there is no cure for PCA and that evidence for medicines specifically in PCA is limited. Doctors may consider medicines based on the underlying disease and individual circumstances; people should discuss medical decisions with a qualified clinician.
Source: beingpatient.com
